Literature DB >> 31249456

2019 Consensus of the Taiwan Hypertension Society and Taiwan Society of Cardiology on the Clinical Application of Central Blood Pressure in the Management of Hypertension.

Hao-Min Cheng1,2,3, Shao-Yuan Chuang4, Shih-Hsien Sung1,5, Chih-Cheng Wu6,7, Jiun-Jr Wang8, Pai-Feng Hsu1,9, Chia-Lun Chao10, Juey-Jen Hwang11,2, Tzung-Dau Wang12, Chen-Huan Chen1,3.   

Abstract

The Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) have appointed a joint consensus group for the 2019 Consensus of the TSOC and THS on the Clinical Application of Central blood pressure (BP) in the Management of Hypertension with the aim of formulating a management consensus on the clinical application of central BP in the management of hypertension. This consensus document focuses on the clinical application of central BP in the care of patients with hypertension. The major determinants of central BP are increased arterial stiffness and wave reflection, which are also the dominant hemodynamic manifestations of vascular aging. Central BP can be measured noninvasively using various techniques, including with convenient cuff-based oscillometric central BP monitors. Noninvasive central BP is better than conventional brachial BP to assess target organ damage and long-term cardiovascular outcomes. Based on the analysis of long-term events, a central BP threshold of 130/90 mmHg for defining hypertension has been proposed. Recent studies have suggested that a central BP strategy to confirm a diagnosis of hypertension may be more cost-effective than conventional strategies, and that guiding hypertension management with central BP may result in the use of fewer medications to achieve BP control. Although noninvasive measurements of brachial BP are inaccurate and central BP has been shown to carry superior prognostic value beyond brachial BP, the use of central BP should be justified in studies comparing central BP-guided therapeutic strategies with conventional care for cardiovascular events.

Entities:  

Keywords:  Brachial BP; Central BP; Diagnosis; High BP; Hypertension; Management; Peripheral BP

Year:  2019        PMID: 31249456      PMCID: PMC6533580          DOI: 10.6515/ACS.201905_35(3).20190415B

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  4 in total

1.  Prevalence, Treatment, Control and Monitoring of Hypertension: A Nationwide Community-Based Survey in Taiwan, 2017.

Authors:  Heng-Yu Pan; Hung-Ju Lin; Wen-Jone Chen; Tzung-Dau Wang
Journal:  Acta Cardiol Sin       Date:  2020-07       Impact factor: 2.672

2.  2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension.

Authors:  Tzung-Dau Wang; Chern-En Chiang; Ting-Hsing Chao; Hao-Min Cheng; Yen-Wen Wu; Yih-Jer Wu; Yen-Hung Lin; Michael Yu-Chih Chen; Kwo-Chang Ueng; Wei-Ting Chang; Ying-Hsiang Lee; Yu-Chen Wang; Pao-Hsien Chu; Tzu-Fan Chao; Hsien-Li Kao; Charles Jia-Yin Hou; Tsung-Hsien Lin
Journal:  Acta Cardiol Sin       Date:  2022-05       Impact factor: 1.800

Review 3.  Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe.

Authors:  Donna S-H Lin; Tzung-Dau Wang; Peera Buranakitjaroen; Chen-Huan Chen; Hao-Min Cheng; Yook Chin Chia; Apichard Sukonthasarn; Jam Chin Tay; Boon Wee Teo; Yuda Turana; Ji-Guang Wang; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-12-11       Impact factor: 3.738

4.  Comparison of Risk of Target Organ Damage in Different Phenotypes of Arterial Stiffness and Central Aortic Blood Pressure.

Authors:  Yaya Bai; Qian Wang; Di Cheng; Yueliang Hu; Huijuan Chao; Alberto Avolio; Biwen Tang; Junli Zuo
Journal:  Front Cardiovasc Med       Date:  2022-04-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.